- December 17, 2025
-
-
Loading
Loading
TAMPA —Alzamend Neuro has received permission from the U.S. Food and Drug Administration to move forward with a Phase 1 clinical study of AL001, a treatment for patients with Alzheimer’s disease and dementia.
In a statement released to investors Wednesday afternoon, CEO Stephan Jackman thanked the FDA for its expediency and says, “We are advancing the process and expect that the first patient will be dosed in September 2021.”
